Efficacy of Electrochemotherapy with Bleomycin to the Murine Osteosarcoma Model by 石川  朗 et al.
Efficacy of Electrochemotherapy with Bleomycin to the Murine Osteosarcoma Model
－ 9 －
Introduction
　Osteosarcoma is the most common primary 
malignant tumor of bone in children and young adults 
and requires aggressive treatment due to its clinical 
behavior. Before the 1970s, osteosarcoma patients 
were mainly treated with amputation, and the five-
year survival rate was less than 20% due to 
uncontrolable metastases. Postoperative adjuvant 
chemotherapy improved the prognosis during the 
1970s1). In 1979, Rosen et al. advocated preoperative 
chemotherapy or neoadjuvant chemotherapy2). After 
the introduction of these combined approaches with 
surgery and chemotherapy, wide resection of the 
tumor and limb-sparing operations with endoprosthe-
sis were generaly applied, and the prognosis of 
patients with a localized osteosarcoma improved to a 
five-year survival rate of 50-60%3), 4).
　It  is  believed  that  the  cel  membrane  of 
osteosarcoma cels lacks the membrane proteins that 
participate in the membrane transport of drugs, 
which reduces the drug transport into the cels for 
cancer chemotherapy1). Because of the low permeabil-
ity of the osteosarcoma cels to anticancer drugs, high 
dosages of these drugs have been used in the 
chemotherapy for osteosarcoma. However, this has 
not proven to be a solution to the problem of treating 
osteosarcoma. 
　However, a new mode of treatment to enhance the 
cytocidal efects employing electrical pulses has been 
introduced in cancer chemotherapy in the past recent 
decade5), 6). This electrical pulse, generaly termed 
electroporation, leads to the transient formation of a 
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pore on the cel membrane, and has been established 
in the area of genetic engineering as a means to raise 
the " in-flow " of a substance through cel membranes. 
Electroporation has commonly been applied for 
purposes such as the genetic transduction of DNA 
into cels7), 8). With regard to the application of this 
technique to cancer chemotherapy, there have been 
reports on electrochemotherapy (ECT) in which 
electroporation was employed in squamous cel 
carcinoma to enhance the transport of bleomycin 
(BLM), which is a water-soluble drug that normaly 
resists permeation through the lipid bilayer of the cel 
membrane into cancer cels9)－11). There have also been 
reports12), 13) of the treatment of sarcoma-bearing 
animals that described a high response rate of these 
tumors. The use of ECT in the reports provided 
advantages of a high eficacy of treatment, a decrease 
in the efective drug dose and a reduction of toxicity 
and side efects.
　In clinical practice, BLM has been administered for 
the treatment of osteosarcoma, mainly in advanced 
cases with pulmonary metastasis14). Meanwhile, 
Rosen et al.2) stated that BLM was efective against 
the primary foci of osteosarcoma. However, there 
have been no reports on the detailed mechanisms by 
which BLM exerts its antineoplastic efects against 
osteosarcoma.
　We considered the feasibility of applying electropo-
ration as a means to enhance the BLM transport into 
osteosarcoma cels, and conducted a study of ECT in a 
murine osteosarcoma model. The present study is the 
first trial to apply in vivo ECT with BLM for 
osteosarcoma. We chose to use BLM for this animal 
study on osteosarcoma, because the osteosarcomas 
have been reported to lack the membrane protein 
responsible for drug permeability, and BLM is poorly 
transported through the lipid bilayer of the cel 
membrane.
　We observed the sequential changes of the tumor 
volume, the tissue concentration of BLM and the 
changes in histology to evaluate the eficacy of ECT 
with regard to the intracelular transport of BLM.
Materials and Methods
Animals　Female, five-week-old, SCID mice (Fox 
Chase SCID C.B-17/Icr-scid Jcl) were obtained from 
Japan Clea, and had an average weight of 25.0 g 
(range 21.0-27.6 g). These animals were housed under 
specific-pathogen free conditions because they had 
severe combined immunodeficiency and lacked both 
mature T cels and B cels.
Tumor　The tumor was a surgical sample that had 
been colected from a patient with osteosarcoma of 
the osteoblastic type located at a proximal humerus. 
For preoperative chemotherapy, cis-diamminedichlo-
roplatinum was given once, and high doses of 
methotrexate-citrovorum  factor  rescue  therapies 
were given twice. The tumor continued to grow in 
spite of the chemotherapy, and the patient was 
subjected to a scapulo-thoracic transection. A sample 
was colected from the lesion of the amputated limb 
for use in the present study. The material was 
transferred into culture medium (Dulbecco's Modified 
Eagle Medium: Gibco BRL). The tumorous lump was 
minced into fine pieces and passed through an 18-
gauge needle. Minced tumor mixed with media was 
injected subcutaneously into the back of each mouse. 
SCID mice were anesthetized in the contained filed 
with diethylether gas before the tumor implantation. 
Two weeks after the implantation of the osteosarco-
ma, solid and almost round tumors had developed on 
the back, with an average diameter of 6 mm (range 5-
11 mm). At this time, the experimental treatment 
were started. 
Electrochemotherapy (ECT)　SCID mice were anes-
thetized with Nembutal® (Pentobarbital sodium 
solution, Dainippon Sumitomo Pharma Co. Ltd., 
Japan, contents of 50 mg/ml) at a dose of 0.5 mg/10 g 
body weight intraperitonealy. A total of 24 animals 
with established tumors were then classified into four 
diferent treatment groups, as folows:
a) Bleomycin (BLM) treatment : The dose of BLM, 
which was generously provided by NIPPON KAYAKU 
Co. Ltd., Japan, was set at one tenth of the dose that 
was lethal to 50% of mice (LD50) per animal. The 
dose of 0.25 mg BLM was dissolved in 100μl of 
physiological saline per animal (10 mg/kg), and was 
injected via an intramuscular route into the right 
femoral area. The groups that received BLM were 
designated as D(+) and the groups that did not was 
D(-).
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b) Electroporation (EP) treatment : The EP was 
started at 30 minutes after the injection of BLM into 
each SCID mouse. This 30-minutes interval was 
necessary to obtain the maximum blood concentra-
tion of BLM after intramuscular injection15). A pulse 
generator (Electro Square Porator T820, Genetronics, 
Inc. USA) was used to deliver exponential pulses of 
variable voltage (500-3000 volts) and duration (0.99-
99 miliseconds). Needle electrodes (Unique Medical 
Imada Inc. Sendai, Japan) made of stainless steel 
(Figure 1), which were inserted through the skin so 
that they were located on each side of the 
subcutaneous tumor at its maximum diameter. Eight 
exponential pulses of 1000 volt/cm for 99μ seconds 
were given at 1Hz. The groups that were subjected to 
EP were designated as E(+), and those without were 
designated E(-).
c) Experimental Groups : These animals were as-
signed to the BLM plus EP group (D(+)E(+)), a 
group that received BLM without EP (D(+)E(-)), a 
group that was subjected to EP alone (D(-)E(+)), or a 
group that received neither BLM nor EP treatment 
(D(-)E(-)). The number (n) of SCID mice in each 
group was set at 6.
d) Tumor Size : With the maximum long axis of the 
tumor  designated  as  A  (mm)  and  the  axis 
perpendicular to A designated as B (mm), the volume 
V (mm3) was determined from the formula; V = 
πA×B2/6. Setting the volume at the start of the 
experiment at 1, the tumor size was determined 
sequentialy as the changes from the start that were 
computed in volume ratios.
Tissue Concentration of BLM　The tissue concentra-
tion of BLM(μg/g) was determined by a microbiologi-
cal analysis based on the Bacilus subtilis growth 
inhibitory concentration of the BLM16) that had been 
extracted from the tumor and muscle. In the 
D(+)E(+) group, the tumor was immediately excised 
after EP. In the D(+)E(-) group, the tumor was 
excised at 30 minutes after the intramuscular 
injection of BLM. At the same time, the muscle was 
excised from the left femoral regions where no BLM 
had been injected, and was used as the control for an 
analysis of the intramuscular concentration of BLM. 
The tumor and muscle were excised, their weights 
were measured, and they were immediately stored at 
－80℃. For the bioassay of the BLM, tumor tissues 
were homogenized in 7.5% trichloracetic acid at two-
folded the volume of the tumor. Each lysate was 
centrifuged at 10000 rpm for 10 minutes at 4℃, and 
the supernatant was neutralized with 1000 ml of 
bufer (30.8 g of KOH, 18 mg of phenol red, 0.067 M 
Figure 1. A set of needle electrode
A needle electrode is made of stainless steel with insulated handle, and its tip is coated by gold. The two electrodes 
can be fixed by a plastic shank fixture.
A : Code
B : Needle electrodes
C: Plastic shank fixture for the needle electrode
D : Magnified image of the tip of electrode
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phosphate bufered saline, pH7.2). The lowest 
measurable level of the concentration of BLM was 0.1-
0.2μg/g. This method had an advantage of not being 
afected by BLM hydrase, a BLM-inactivating 
enzyme, during the extraction. The number of tissue 
samples used for the BLM concentration analysis was 
three each from D(+)E(+) group and D(+)E(-) group. 
NAC Co. Ltd., Japan, kindly analyzed the tissue 
concentrations of BLM.
Tissue preparation　Tumor-bearing SCID mice were 
sacrificed before ECT as a control, and were also 
sacrificed at one week, three weeks and five weeks 
after ECT. The subcutaneous tumors on the backs of 
the mice were excised for the histological analyses. 
These materials were fixed in 4% paraformaldehyde 
for 24 hours, then embedded in parafin. Sections 
were prepared for hematoxylin and eosin (HE) 
staining.
Immunohistochemistry　Additionaly, we performed 
immunohistochemical  staining  for  macrophages 
using KP-1 mouse anti-human antibodies (DAKO 
Japan, Kyoto, Japan), and a secondary biotinylated 
antibody (the avidin-biotin complex staining method).
Statistical analysis　The data are presented as the 
means±SE and were analyzed using the nonparamet-
ric Mann Whitney-U test to compare the tissue 
concentrations of BLM among the groups. These 
statistical  analyses  were  performed  using  the 
StatView J-4.5 software program (Abacus Concepts, 
Inc. Berkeley, USA). Diferences were considered to 
be significant for values of p＜0.05.
Results
　The SCID mice tolerated the treatment wel and 
had no damage to the skin caused by electroporation.
Tumor response　Among the four groups, marked 
tumor reduction was noted only in the D(+)E(+) 
group during the 14-days observation period (Figure 
2). Among the six animals in this group, the tumor 
was eliminated completely in two animals on Day 10. 
The tumor volume ratio was sequentialy reduced to 
0.023±0.029 on Day 14, showing a significant tumor 
reduction. In the D(+)E(-) group, the tumor 
sequentialy increased in size, and no size reduction 
was noted for any of the tumors. The tumor volume 
ratio of 3.000±1.684 on Day 14. In the D(-)E(+) 
group, the tumors increased in size, and no reduction 
in size was noted. The ratio reached to 2.265±1.789 
on Day 14. The D(-)E(-) group demonstrated a similar 
increase in tumor volume, reaching 3.220±1.683 on 
Day 14, which was the highest among the four groups 
(Figure 3).
Tissue concentrations of BLM　The mean concentra-
Figure 2. Sequential volume change of the tumor
When the tumor volume on day 1 was set at 1, the 
tumor volume ratio was sequentialy changed. On day 
14, the volume ratio was reduced only in D(+)E(+) 
group. Numbers in each column represent the 
mean±SE, n=6.
Figure 3. Volume ratio folowing electrochemotherapy
When the tumor volume ratio on day 1 was set at 1, 
that for the D(+)E(+) group was reduced to 0.023 on 
day 14, showing that the combination with electropo-
ration resulted in a significant reduction in tumor 
volume. The numbers in each column stand for the 
mean±SE, n=6.
★, p<0.01 compared to other group. 
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tion of BLM in the tumor tissue in the D(+)E(-) group 
was 1.153±0.133μg/g, while it was 0.603±0.437μg/g 
in the D(+)E(-) group. These values were signifi-
cantly diferent (★p<0.05). The BLM concentrations 
in the tumor tissues of the D(+)E(+) group were also 
significantly higher than those in the muscular tissue 
used as a control (★★p<0.01). This diference was 
also found in the D(+)E(-) group. In the D(+)E(+) 
and D(+)E(-) groups, the mean BLM concentrations 
of the muscle tissues used as the control were 
0.237±0.195 and 0.223±0.146μg/g, respectively, with 
no significant diference between these two values. 
Electroporation did not produce a notable diference 
in the muscle concentration of BLM, which was not 
associated with the sites charged by the electrical 
pulse (Figure 4).
Histology　In view of the histological findings before 
the ECT, the tumor tissue was localized in the fibrous 
capsule, and there were smal cels sporadicaly 
located in the subcutaneous tissue around the tumor 
(as indicated by HE staining). At one week after ECT, 
the tumor tissue had divided into smal lobules, and 
the capsule had changed into a thick band with round 
cel infiltration. At three weeks, there were massive 
hemorrhage and necrosis in the tumor tissue, and 
large monocytes were found around the tumor. At five 
weeks, the tumor cels had disappeared and monocyte 
infiltration occupied the entire region. In an 
investigation of the macrophage level determined by 
specific immunostaining (KP-1), infiltrating mono-
cytes were identified at three weeks, and occupied the 
whole area at five weeks (Figure 5). In terms of the 
macroscopic findings, the tumor tissues were almost 
completely eradicated, with only traces of fibrous 
tissue stil present at five weeks after ECT.
　Based on these observations, it was concluded that 
electroporation after the intramuscular injection of 
BLM incresed the BLM concentration in the 
subcutaneous tumor tissue on the backs of SCID 
mice, thus alowing the drug to exert a more potent 
cytocidal efect against the osteosarcoma cels.
Discussion
　The present study, the first trial to apply ECT to 
osteosarcoma in a murine model, indicated that BLM 
Figure 4. Tissue concentration of BLM
In one group, BLM was injected and folowed by 
electroporation. In the other group, electroporation 
was omitted. In the former group, the BLM 
concentration in the tumor tissue was significantly 
raised. The tumor tissue concentration of BLM also 
exceeded that of the muscle tissue. No effects of 
electroporation were noted in the muscle tissue 
concentration that was used as the control. The 
numbers in each column represent the mean±SE, n= 
3. 
★, p<0.05 compared with electroporation or not.
★★, p<0.01 compared with tumor and muscle tissue.
Figure 5. Histological changes
HE staining; a (before ECT), b (after 1 week), c (after 3 weeks), d (after 5 weeks), ×400
KP-1 staining; e (before ECT), f (after 1 week), g (after 3 weeks), h (after 5 weeks), ×400
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could be detected at high concentrations in the 
osteosarcoma tissue, and that the tumor volume was 
reduced (or the tumors were completely eliminated) 
in less than two weeks from the start of treatment. 
This was considered to be due to the increased 
permeation of BLM into the tumor tissue, alowing it 
to exert cytotoxicity as an antineoplastic agent.
　BLM is characterized by its specific pharmacokinet-
ics and tissue afinity, and is distributed uniquely to 
each organ, with relatively high concentrations found 
in the lungs and skin, but has been shown to have 
almost no accumulation in bone marrow15), 17). We 
interpret the high concentration of BLM found in the 
osteosarcoma tissue in our specimens as folows: the 
afinity of BLM for osteosarcoma is greater than for 
muscle tissue as our data demonstrate that the 
concentration of BLM in osteosarcoma tissue without 
electroporation was 0.603±0.437μg/g, while that of 
BLM in muscle tissue was 0.223±0.146μg/g under 
the same condition. We postulate that the accumula-
tion of BLM in the osteosarcoma tissue through the 
enhancement by electroporation was further exagger-
ated by this tissue afinity. Due to the low 
permeability through the lipid bilayer, the BLM that 
flowed into the cels at a high concentration folowing 
ECT was prohibited from being transported back out 
of these cels after the resealing of the membranes; 
thus the agent tended to remain in the tumor cels for 
a prolonged period, which alowed it to exert its 
antineoplastic efects on the osteosarcoma.
　Recently, there have been some reports that 
electrical pulses might provoke the closure of vessels 
aferent to the electropulsed area18)－20). This arterial 
closure might reduce the size of the tissue, while the 
venous occlusion would cause local congestion and 
edema, which would also have anti-tumor efects. In 
the present study, the tumor volume of the D(-)E(+) 
group ilustrated exponential growth, but its growth 
was decreased compared to that of the D(-)E(-) group. 
This support the idea that the efects of electropora-
tion to the tumor might have led to vasospasms, and 
caused this growth suppression.
　Histologicaly, the macrophage infiltration in the 
later period of observation after ECT with BLM 
indicated the possibility that there was immunore-
sponse involving the tumoricidal activity of macro-
phages21). According to Morikawa, et al.22), BLM 
therapy activated tumoricidal macrophages that 
might participate in the host-mediated antitumor 
efects of BLM lately. In the present study, 
macrophage infiltration was observed beginning at 
three weeks after ECT, so this reaction might be a 
secondary tumoricidal response to the combination of 
electrochemotherapy and BLM.
　Theses results of the present study demonstrate 
that BLM accumulates in the tumor cels due to the 
agent's afinity for osteosarcoma, which is further 
enhanced by electroporation, thus achieving a potent 
antineoplastic efect. We conclude that electrochemo-
therapy with bleomycin may be an efective mode of 
treatment against osteosarcoma. Further studies are 
warranted to confirm the safety and eficacy of this 
treatment.
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